

# ISPOR 43rd Health Technology Assessment Roundtable [Europe]

Sunday, 11 November 2018 – 08:30 – 17:30 Centre de Convencions Internacional de Barcelona (Room: 212) Barcelona, Spain

<u>Chair</u> **Wim Goettsch, PhD, MSc** Special Advisor, HTA **Zorginstituut Nederland (ZIN)** Diemen, Netherlands

<u>HTA Council Chair</u> **Professor Finn Børlum Kristensen, MD, PhD** Professor, Faculty of Health Sciences **University of Southern Denmark** Odense, Denmark

European Commission Flora Giorgio Policy Officer, DG Sanco European Commission Brussels, Belgium

<u>World Health Organization</u> Sarah Garner, PhD, BPharm Coordinator, Innovation, Access and Use, Essential Medicines and Health Products World Health Organization Geneva, Switzerland

<u>EUnetHTA</u> Luciana Ballini, MSc Chair, EUnetHTA JA3 Plenary Assembly Senior Researcher, Regional Agency for Health (ASSR) Emilia Romagna, Italy



<u>Invited Speakers</u> **Patricia Danzon, PhD** Celia Moh Professor Emeritus, The Wharton School **University of Pennsylvania** Philadelphia, PA, USA

Jan Geissler Chair, ISPOR Patient Representatives Roundtable - Europe Co-founder, CML Advocates Network Board Member, Acute Leukemia Advocates Network Co-Chair FUTURES Team, EUPATI CEO, Patvocates Munich, Germany

Pall Jonsson, PhD, MSc Associate Director National Institute for Health and Clinical Excellence (NICE) Manchester, England, United Kingdom

**Amr Makady, PhD, PharmD** Pharmacoeconomic Assessor & Policy Advisor **Zorginstituut Nederland (ZIN)** Diemen, Netherlands

Harriet Unsworth, PhD
Senior Technical Analyst, Medical Technologies
National Institute for Health and Clinical Excellence (NICE)
Manchester, England, United Kingdom

Shirley Wang, PhD, ScMEpidemiologist, Division of Pharmacoepidemiology and PharmacoeconomicsBrigham & Women's HospitalBoston, MA, USA



<u>Austria</u> Gottfried Endel, MD Head of Department for Evidence Based Economic Health Care Main Association of Austrian Social Security Institutions Vienna, Austria

**Ingrid Rosian-Schikuta, Mag** Deputy Head, Health Economics Department **Gesundheit Österreich GmbH (GÖG)** Vienna, Austria

<u>Belgium</u> **Francis Arickx** Head, Directorate Pharmaceutical Policy **National Institute for Health and Disability Insurance (RIZIV INAMI)** Brussels, Belgium

Frank Hulstaert, MD, MSc Senior Researcher Federal Centre for Health Care Knowledge (KCE) Brussels, Belgium

Bosnia and Herzegovina Siniša Stević, MD, MS Director Agency for Certification, Accreditation and Health Care Improvement (ASKVA) Banja Luka, Bosnia and Herzegovina

<u>Croatia</u> **Mirjana Huić, MD, PhD** Clinical Pharmacologist and Toxicologist Assistant Director, Department for Development, Research and Health Technology Assessment **Agency for Quality and Accreditation in Health Care and Social Welfare** Zagreb, Croatia



Jelena Matuzović, dr med Head, Department for Medicines Croatian Institute for Health Insurance Zagreb, Croatia

<u>Denmark</u> Camilla Nielsen, PhD, MSc Research Director, Health Technology Assessment & Health Services Research DEFACTUM Aarhus, Denmark

<u>Finland</u> **Piia Rannanheimo, MSc** Pharmacoeconomist **Finnish Medicines Agency (FIMEA)** Kuopio, Finland

**Miia Turpeinen, MD, PhD, MBA** Head **National HTA Coordination Unit (FinCCHTA)** Oulu, Finland

<u>France</u> Chantal Guilhaume, PharmD Scientific Project Manager, EUnetHTA JA3 Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France

<u>Germany</u> **Dr. Veronika Deák** Scientific Advisor **Gemeinsamer Bundesausschuss (G-BA, Federal Joint Committee)** Berlin, Germany

Alric Rüther, dr med, PhD Head, International Affairs Institute for Quality and Efficiency in Health Care (IQWiG) Cologne, Germany



<u>Greece</u> **Spyridon Goulas, MD** Supervisor **National Organization for Health Care Provision (EOPYY)** Athens, Greece

<u>Hungary</u> Fanni Ispán, MSc Reimbursement Analyst National Health Insurance Fund of Hungary Budapest, Hungary

Gergő Merész, MSc Head, Department of Health Technology Assessment National Institute of Pharmacy and Nutrition (NIPN) Budapest, Hungary

#### <u>Ireland</u>

**Lesley Tilson, PhD, BSc Pharm (Hons)** Deputy Director, National Centre for Pharmacoeconomics **St. James's Hospital** Dublin, Ireland

<u>Italy</u> **Agnese Cangini, MSc** Health Economist **Agenzia Italiana del Farmaco (AIFA)** Rome, Italy

<u>Kazakhstan</u> **Kamilla Gaitova, PhD, MSc** Head, HTA Department **Republican Center for Health Development, Ministry of Health** Astana, Kazakhstan



<u>Latvia</u> **Kristīna Brūvere** Senior Expert, Department of Pharmacy **Ministry of Health of Latvia** Riga, Latvia

<u>Malta</u> **Antonia Formosa** Director, Pharmaceutical Affairs **Ministry of Health** Valletta, Malta

**Sylvana Magrin Sammut, MSc** Senior Pharmacist, Department Pharmaceutical Affairs **Ministry of Health** Valletta, Malta

<u>Netherlands</u> **Saskia Knies, PhD, MPhil** Senior Pharmacoeconomic Assessor **National Health Care Institute (ZIN)** Diemen, The Netherlands

<u>Norway</u> **Krystyna Hviding, PhD** Senior Advisor – HTA, HTA Unit **Norwegian Medicines Agency** Oslo, Norway

Øyvind Melien, MD, PhD, MSc Department Director, Reviews and HTA Norwegian Institute of Public Health Oslo, Norway



<u>Poland</u> **Iga Lipska, MD, PhD** Member, Economic Commission, **Ministry of Health Poland** Chief Expert, **National Health Fund** Warsaw, Poland

**Roman Topór-Mądry, MD, PhD** President **Agency for Health Technology Assessment and Tariff System (AOTMiT)** Warsaw, Poland

<u>Portugal</u> **Rui Santos Ivo, PharmD** Vice President **INFARMED** Lisbon, Portugal

<u>Romania</u> Silvia Gabriela Scintee, MD, PhD, MSc Deputy General Director National School of Public Health Bucharest, Romania

Russian Federation

### George Khachatryan, MD

Deputy Director, Department of Comprehensive Health Technology Assessment, FSBI "Center of Healthcare Quality Assessment and Control"

Ministry of Health of the Russian Federation

Moscow, Russia

### Vitaly Omelyanovskiy, MD, PhD, DSc

General Director, Department of Comprehensive Health Technology Assessment, FSBI Center of Expertise and Quality Control of Medicines, **Ministry of Health of the Russian Federation** Head, Financial Scientific Research Institute, **Ministry of Finance of the Russian Federation** Head, Center for Health Technology Assessment, **Russian Presidential Academy of National Economy and Public Administration** 

Moscow, Russia



<u>Serbia</u>

Dragana Atanasijevic, MD, MSc Health Technology Assessment Expert National Institute for Public Health Belgrade, Serbia

<u>Slovakia</u>

**Tomas Tesar, PharmD, PhD, MBA** Member, Reimbursement Committee **Union Health Insurance Fund** Bratislava, Slovakia

<u>Slovenia</u> Jure Mikolič, MA Pharm Pharmacy Manager, Department of Medicine Health Insurance Institute Slovenia Ljubljana, Slovenia

Andrej Janžič, PhD, mag farm Division for Pharmacoeconomics, Market Monitoring, and HTA Agency for Medicinal Products and Medical Devices of the Republic of Slovenia Ljubljana, Slovenia

<u>Spain</u> **Iñaki Imaz-Iglesia, MD, PhD** Senior Researcher **Instituto de Salud Carlos III (AETS-ISCIII)** Madrid, Spain

Leonor Varela Lema, PharmD, MSc International Project Manager, Scientific Advice Unit Galician Agency for Health Technology Assessment (AVALIA-T) Santiago de Compostela, Spain



Mireia Espallargues Carreras, MD, PhD Responsible, Health Technology and Quality Assessment Agency for Health Quality and Assessment of Catalonia (AQuAS) Barcelona, Spain

<u>Sweden</u> Sophie Werkö, PhD, MSc Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Chair, The International Network of Agencies for Health Technology Assessment (INAHTA) Stockholm, Sweden

#### <u>Turkey</u>

Rabia Kahveci, MD, MScHTA Professor, Ankara Numune Hospital Chair, ANHTA (Ankara Numune HTA Unit) Consultant, HTA Unit, Ministry of Health (Agency for Pharmaceuticals and Medical Devices) Director, HTAi Ankara, Turkey

### <u>Ukraine</u>

### Oresta Piniazhko, PhD, PharmD

Senior Lecturer, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Postgraduate Faculty, **Danylo Halytsky Lviv National Medical University** Member of Expert Committee, **Ministry of Health of Ukraine** Lviv, Ukraine

### United Kingdom

Meindert Boysen, PharmD, MSc Director, Centre for Health Technology Evaluation National Institute for Health and Clinical Excellence (NICE) Manchester, England, United Kingdom

Anne Lee Chief Pharmacist Scottish Medicines Consortium (SMC) Glasgow, Scotland, United Kingdom



Observer David Rogers, MBA Policy Analyst Bermuda Health Council

Hamilton, Bermuda

### ISPOR Staff

Nancy Berg, CEO & Executive Director
 Nadia Naaman, Senior Director, Scientific and Health Policy Initiatives
 Julia Chamova, MBA, Director, Global Networks – Europe, Middle East, and Africa
 Kelly Lenahan, MPH(c), Manager, Scientific and Health Policy Initiatives